TMCnet News
Adverum Biotechnologies Announces Data Presentations at ARVO 2020REDWOOD CITY, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced presentations on the company’s gene therapy programs to be presented at the Association for Vision and Ophthalmology (ARVO) 2020 Congress in Baltimore, MD. Oral Presentation Title: Phase 1 Study of Intravitreal Gene Therapy ADVM-022 for Neovascular AMD (OPTIC Trial) Poster Title: Intravitreal Delivery of AAV2.7m8. Ranibizumab Suppresses Exudative Lesions in the NP Laser Induced Model of nAMD Poster Session: Gene Therapy and Delivery (Session #488) Date: Wednesday, May 6, 2020 Time: 3:00 – 4:45 p.m. ET Poster Title: Mouse Studies Support Intravitreal Gene Therapy for Blue Cone Monochromacy About Adverum Biotechnologies Investor and Media Inquiries: Investors: Media:
|